Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion.
Anthony Joseph EspositoJewel ImaniShikshya ShresthaShefali BagweAnthony M LamattinaMarina ViveroHilary J GoldbergIvan O RosasElizabeth P HenskeSouheil Youssef El-ChemalyPublished in: Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia (2023)
Our results suggest that FGF23 is associated with pulmonary diffusion abnormalities in LAM patients and elicit novel mechanisms of LAM pathogenesis. FGF23 alone or in combination with other molecules needs to be validated as a biomarker of LAM activity in future clinical research.